Neurenati Therapeutics
- 01/03/2024
- Seed
- $1,200,000
Neurenati develops novel therapies for GI rare diseases
- Industry Biotechnology Research
- Website https://www.neurenati.com/
- LinkedIn https://www.linkedin.com/company/neurenati/
Related People
Maxime RangerFounder
Serial entrepreneur who turned into venture capitalist in the life science space, specialized in the drug development: oncology, hepatology, gastroenterology and metabolic conditions, such as NASH, Prader-Willi Syndrome, type-2 diabetes and obesity. MBA, Ph.D. chemist with a scientific background in Material Sciences, more particularly in polymer chemistry. Two postdoc internships oriented to drug delivery, formulation development and nanolithography. Experience now extended to due diligence investigation, drug hunting and start-up financing. Co-authors of 30+ scientific publications in international peer-reviewed journals and co-inventors of 9 PCT-patented technologies.
Specialties: CMC, formulation development, drug delivery, IND-enabling preclinical studies, clinical development strategies (Phase I & II). Pre-Seed, Seed, Series A/B Fundraising, Corporate affairs, licensing activities and IP strategy.